Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MLF1
REST API REST API
Homo sapiens
MLF1 is differentially expressed in 279 experiments: 133 organism parts: liver, placenta, ... (131 more);, 242 disease states: normal, acute myeloid leukemia, ... (240 more);, 94 cell types 492 cell lines 40 compound treatments and 69 other conditions.
Orthologs Mlf1 (Rattus norvegicus)   MLF1_BOVIN (Bos taurus)   Mlf1 (Mus musculus)   ENSCING00000017584 (Ciona intestinalis)   MLF1 (Danio rerio)   MLF1 (Gallus gallus)   ENSCING00000012373 (Ciona intestinalis)   Mlf (Drosophila melanogaster)   A9JSC1_XENTR (Xenopus laevis)   MLF1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, protein binding, cytoplasm, transcription, DNA-dependent, cell cycle arrest, protein domain specific binding, cell differentiation, cell cycle, multicellular organismal development, nucleus, myeloid progenitor cell differentiation
UniProt Accession Q96MH1, C9J3M3, Q2TLE3, Q2TLE5, C9K0D3, C9K0D4, C9JNE5, P58340, Q8N8F8, E7ESR4, F8WEY0, F8VXT4
Gene-Disease Assocation LEUKEMIA, ACUTE MYELOID; AML
InterPro Term Myeloid_leukemia_factor
Search EB-eye ENSG00000178053
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (44 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-19639, E-GEOD-20081, E-GEOD-3529
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
SW480
1
3
E-MEXP-1014, E-GEOD-2509, E-GEOD-18005, E-MTAB-37
HCC2157
2
E-MTAB-37, E-MTAB-62
HCC38
2
E-MTAB-37, E-MTAB-62
KG1
2
E-MTAB-37, E-GEOD-24147
486 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-500, E-GEOD-21668, E-GEOD-19397, E-GEOD-3920, ... (43 experiments)

Factor Value U/D Experiments
monocyte
2
E-GEOD-7307, E-GEOD-11755
fibroblast
2
E-GEOD-3920, E-GEOD-3204
1
2
E-TABM-130, E-TABM-145
endothelial cells and pericytes
1
E-MEXP-1251
Leukocytes
1
E-GEOD-21909
bone marrow CD34+ cell
1
E-GEOD-500
88 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-16363, E-GEOD-3678, E-MTAB-62, E-GEOD-5418, ... (53 experiments)

Factor Value U/D Experiments
prostate cancer
2
E-GEOD-6919, E-MTAB-62
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
chronic myelogenous leukemia
2
E-MTAB-62, E-GEOD-96
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
control
2
E-GEOD-21912, E-GEOD-16363
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
236 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-5258, E-TABM-782, E-GEOD-3720, E-MEXP-1958, ... (25 experiments)

Factor Value U/D Experiments
5-aza-2'-deoxycytidine
3
2
E-GEOD-5230, E-MEXP-1269
5-aza-2'-deoxycytidine + trichostatin A
1
2
E-MEXP-1269, E-GEOD-5230
none
3
4
E-TABM-782, E-GEOD-412, E-MEXP-1269, E-MEXP-1958, E-GEOD-20719, ... (7 experiments)
4OH-tamoxifen
1
E-GEOD-2292
hydrogen peroxide
1
E-GEOD-5339
tBHP
1
E-MEXP-2345
34 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
not specified
1
1
E-GEOD-21521
LT6
1
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (7 experiments)

Clinical info
studied in E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-20499, E-GEOD-21589, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-4667, E-MEXP-2283, ... (6 experiments)

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-GEOD-22148, ... (8 experiments)

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-GEOD-6431, ... (7 experiments)

Genotype
studied in E-TABM-1029, E-MEXP-1996, E-GEOD-22593, E-TABM-868, E-GEOD-18005, ... (15 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-GEOD-6432, E-TABM-127, E-GEOD-20540, E-GEOD-20504, ... (9 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-GEOD-5764, E-GEOD-1926, E-MEXP-2069, E-MEXP-1648, ... (30 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-MEXP-561

Karyotype
studied in E-GEOD-7214, E-GEOD-12662

Labeling
studied in E-LGCL-5

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-26495, E-GEOD-21750, E-GEOD-2487

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Replicate
studied in E-GEOD-10797

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307, E-GEOD-1295

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, ... (6 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-6532, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.491 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM